David Dornan
Vermogen: 1 917 $ op 30-06-2025
Vermogen: 1 917 $ op 30-06-2025
David Dornan currently works at Whitehawk Therapeutics, Inc., as Chief Scientific Officer from 2025.
Dr. Dornan also formerly worked at Gilead Sciences, Inc., as Director & Head-Oncology Research from 2012 to 2017, Bolt Biotherapeutics, Inc., as Senior Vice President-Research & Manufacturing, and Elevation Oncology, Inc., as Chief Scientific Officer from 2022 to 2025.
Dr. Dornan received his doctorate degree from the University Of Dundee and undergraduate degree from the University of Strathclyde.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-03-2025 | 5.223 ( 0,01% ) | 1 917 $ | 30-06-2025 |
| Bedrijven | Functie | Begin |
|---|---|---|
| WHITEHAWK THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 18-02-2025 |
| Bedrijven | Functie | Einde |
|---|---|---|
| ELEN ONCO | Hoofd Techniek/Wetenschap/O&O | 17-02-2025 |
| BOLT BIOTHERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 11-03-2022 |
| GILEAD SCIENCES, INC. | Directeur/Bestuurslid | 01-11-2017 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 6 |
|---|---|
Gilead Sciences, Inc.
Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
University Of Dundee
University Of Dundee Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Strathclyde
University of Strathclyde Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company | Health Technology |
Elevation Oncology, Inc.
Elevation Oncology, Inc. BiotechnologyHealth Technology Develops elevating precision medicines for cancer treatment | Health Technology |
Aadi Bioscience, Inc.
Aadi Bioscience, Inc. BiotechnologyHealth Technology Develops mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau